3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
69
Bevacizumab
40
Radiotherapy
22
Magnetic Resonance Spectroscopy
20
Irinotecan
17
Specimen Handling
10
Carboplatin
10
Carmustine
9
X-Rays
7
Radiation
7
olaparib
6
Surgical Procedures, Operative
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Nivolumab
6
Everolimus
6
Cyclophosphamide
6
Biopsy
6
trametinib
5
Thalidomide
5
Cisplatin
5
pembrolizumab
4
palbociclib
4
fluorodopa F 18
4
erdafitinib
4
dabrafenib
4
Lomustine
4
Etoposide
4
Drug Therapy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled